Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Jan 6, 2017 | 1:52 PM EST
The market continues to grind higher by the hour. All the major indices are up nicely as we head into the last two hours of trading of what has…
By

Bret Jensen

 | Jan 6, 2017 | 11:55 AM EST
Not much action in the markets since our last update with the major indices continuing to grind slightly higher as we try to close out a solid…
By

Bret Jensen

 | Jan 6, 2017 | 10:31 AM EST
The December jobs report comes in slightly below the consensus. However, with the revisions to the prior two months, jobs are higher for past three…
RMPIA
By

Bret Jensen

 | Jan 6, 2017 | 8:22 AM EST
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages.…
RMPIA
By

Bret Jensen

 | Jan 6, 2017 | 7:18 AM EST
It is good to be here once again on a Friday filling in for Doug Kass. It has been an interesting and mostly up opening week for investors in 2017. We…
By

Bret Jensen

 | Jan 5, 2017 | 12:00 PM EST
M&A activity should perk up substantially in the small and mid-cap space this year.
By

Bret Jensen

 | Jan 5, 2017 | 9:44 AM EST
Markets pretty flat at open as we try to continue the rally.  Biotech going for three big up days in a row and is up nicely again in early...
By

Bret Jensen

 | Jan 4, 2017 | 12:03 PM EST
Market rallying for second day in a row to begin 2017. What a difference a year makes as far as biotech is concerned.  Second day of large...
By

Bret Jensen

 | Jan 3, 2017 | 1:30 PM EST
This biopharma company's Relistor drug should send revenues sharply higher this year.
By

Bret Jensen

 | Jan 3, 2017 | 11:19 AM EST
The first trading day of 2017 is a positive one so far.  All the major indices are up nicely in early trading and oil is approaching $55 a...

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.